Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors by John, Shalini et al.
PROCEEDINGS Open Access
Development, evaluation and application of 3D
QSAR Pharmacophore model in the discovery of
potential human renin inhibitors
Shalini John, Sundarapandian Thangapandian, Mahreen Arooj, Jong Chan Hong, Kwang Dong Kim,
Keun Woo Lee
*
From 22nd International Conference on Genome Informatics
Busan, Korea. 5-7 December 2011
Abstract
Background: Renin has become an attractive target in controlling hypertension because of the high specificity
towards its only substrate, angiotensinogen. The conversion of angiotensinogen to angiotensin I is the first and
rate-limiting step of renin-angiotensin system and thus designing inhibitors to block this step is focused in this
study.
Methods: Ligand-based quantitative pharmacophore modeling methodology was used in identifying the
important molecular chemical features present in the set of already known active compounds and the missing
features from the set of inactive compounds. A training set containing 18 compounds including active and inactive
compounds with a substantial degree of diversity was used in developing the pharmacophore models. A test set
containing 93 compounds, Fischer randomization, and leave-one-out methods were used in the validation of the
pharmacophore model. Database screening was performed using the best pharmacophore model as a 3D
structural query. Molecular docking and density functional theory calculations were used to select the hit
compounds with strong molecular interactions and favorable electronic features.
Results: The best quantitative pharmacophore model selected was made of one hydrophobic, one hydrogen
bond donor, and two hydrogen bond acceptor features with high a correlation value of 0.944. Upon validation
using an external test set of 93 compounds, Fischer randomization, and leave-one-out methods, this model was
used in database screening to identify chemical compounds containing the identified pharmacophoric features.
Molecular docking and density functional theory studies have confirmed that the identified hits possess the
essential binding characteristics and electronic properties of potent inhibitors.
Conclusion: A quantitative pharmacophore model of predictive ability was developed with essential molecular
features of a potent renin inhibitor. Using this pharmacophore model, two potential inhibitory leads were identified
to be used in designing novel and future renin inhibitors as antihypertensive drugs.
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Hypertension is a major factor concerning various cardi-
ovascular diseases such as congestive cardiac failure,
stroke, and myocardial infarction and affects up to 30%
of the adult population in most countries [1]. Renin is an
aspartyl protease and catalytically similar to other
enzymes such as pepsin, cathepsin and chymosin etc [2].
Renin cleaves the angiotensinogen to angiotensin-I which
is then converted to angiotensin-II by the action of
angiotensinogen converting enzyme (ACE). Angiotensin-
II is a biologically active vasopressor recognized by its
receptors which is one of the cascades of events that
leads to the increase in blood pressure. Renin is synthe-
sized as prorenin, a proenzyme, which is transformed
into mature renin by the cleavage of 43 amino acids long
prosegment from the N-terminal end. This conversion of
prorenin to renin occurs in the juxtaglomerular cells of
kidney followed by the release of renin into the circula-
tion [3]. Renin blocks the first and rate-limiting step
which is the conversion of angiotensinogen to angioten-
sin-I. Renin is a very specific enzyme towards its only
known substrate, angiotensinogen, and this remarkable
specificity makes it a very attractive and ideal target to
block the renin-angiotensin system (RAS) [4]. Inhibition
of renin prevents the formation of both angiotensin-I and
II but this is not the case in ACE inhibitors and angioten-
sin receptor blockers, which increase angiotensin-I or/
and II level, respectively. Only renin inhibitors will render
the complete RAS quiescent by suppressing the first step
of the cascade of events. Thus, inhibition of renin would
favor more complete blockade of the system [5]. Potent
inhibitors of this enzyme could therefore provide a new
alternative way to treat hypertension without inhibiting
other biological substances. Aspartyl protease class of
enzymes contains two aspartic acid residues that are
necessary for the activity. Renin enzyme has a bilobal
structure similar to other aspartic proteases and an active
site at the interface. The two important aspartate residues
Asp32 and Asp215 catalyze the proteolytic function of
renin are donated from each lobes of the enzyme [6].
The active site of renin appears as a long, deep cleft that
can accommodate seven amino acid units of the sub-
strate, angiotensinogen, and cleaves the peptide bond
between Leu10 and Val11 within angiotensinogen to gen-
erate angiotensin-I [7]. The approaches followed to
develop early renin inhibitors were based on two meth-
odologies. One is to develop similar peptides to prorenin
as this segment covers the active site of renin prior to the
maturation. The second is based on the N-terminal por-
tion of the substrate, angiotensinogen, for this binds the
active site of renin. But these approaches produced only
weak inhibitors [8]. The first synthetic renin inhibitor
was pepstatin. First-generation renin inhibitors were
peptide analogues of the prosegment of renin or sub-
strate analogues of the amino-terminal sequence of
angiotensinogen containing the renin cleavage site [9].
Crystal structure analyses of renin-inhibitor complexes
and computational molecular modeling were later used
to design selective nonpeptide renin inhibitors that
lacked the extended peptide-like backbone of previous
inhibitor sand had improved pharmacokinetic properties
[10]. Aliskiren is the first of these new nonpeptide inhibi-
tors to be approved by the FDA for the treatment of
hypertension but its synthesis include many steps. This
invites much simpler compounds to be designed as
potent renin inhibitors [11]. Aliskiren belongs to the
third generation of renin inhibitors where the large (high
molecular weight) first and second generation inhibitors
could not be exploited as drugs despite of their potency
in vitro [12]. To date, only few compounds were success-
fully developed with potent renin inhibition profiles, high
efficacy, and safety. Thus designing inhibitors of high
potential for renin inhibition is the most effective way to
block the RAS completely. This study was focused to
identify novel scaffolds with the potential to turn as the
new category of renin inhibitors.
A high-correlation quantitative pharmacophore model
was generated, in this study, using the observed struc-
ture-activity relationship of known renin inhibitors. We
have successfully applied pharmacophore modeling, data-
base screening, molecular docking, and density functional
theory (DFT) calculation methodologies in identifying
lead candidates to be employed in potent renin inhibitor
design and thereby new category of anti-hypertensive
agents.
Methods
Selection of training set compounds
Three dimensional (3D) QSAR strategy is one of the
ligand-based pharmacophore modeling approaches. This
strategy differs from the common feature pharmaco-
phore approach in various points such as limitations of
number of training set compounds and necessity of
experimental activity values predicted using similar
bioassay conditions etc [13]. More than 300 chemical
compounds were retrieved from various literature
resources [14-19] and 111 compounds evaluated with
the same bio-assay protocol were selected to be used as
primary data set in 3D QSAR pharmacophore modeling
study. To ensure the statistical relevance, a training set
containing 18 diverse compounds with the experimental
activity values (IC50) ranging from 0.5 nM to 5590 nM
were selected from 111 dataset compounds and used as
training set (Figure 1) and the remaining 93 compounds
were used as test set compounds to be utilized in phar-
macophore validation.
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The two-dimensional (2D) chemical structures of all the
compounds in the data set were sketched using ChemS-
ketch, version 12 (ACD Inc., Toronto, Canada) and subse-
quently converted to 3D structures in Accelrys Discovery
Studio 2.5 (DS). These 3D compounds were further
checked for the added hydrogens and minimized using
smart minimizer that performs 1000 steps of steepest des-
cent followed by conjugate gradient algorithms with a con-
vergence gradient of 0.001 kcal mol
-1. After energy
minimization, multiple acceptable conformers were gener-
ated for every training set compound within DS Diverse
Conformation Generation module using the Poling algo-
rithm. This step was necessary to produce a good set of
representative conformations of different conformation
space accessible to a molecule within a given energy range.
A maximum of 255 conformations were generated for
each compound within an energy range of 20 kcal mol
-1
above the global energy minimum [20-22].
Generation of pharmacophore models
Among the two types of ligand-based pharmacophore
modeling methodologies, common feature pharmaco-
phore modeling utilizes the common chemical features
present only in the most active compounds whereas the
3D QSAR pharmacophore methodology uses the chemi-
cal features of most active and inactive compounds along
with their biological activity. In this study, we have
employed 3D QSAR-based pharmacophore methodology
to generate pharmacophore models that can be used to
Figure 1 Structure of the training set compounds. 2D Chemical structures of the 18 training set compounds together with their
experimental IC50 values.
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Feature mapping protocol as available in DS was used to
identify the features that are present in the training set
compounds. Uncertainty value was set to 2 and the mini-
mum inter-feature distance was set to 2Å from the
default value of 2.97 Å. As identified by the feature map-
ping protocol, hydrogen bond acceptor (HBA), hydrogen
bond donor (HBD), hydrophobic aliphatic (HY-AL),
hydrophobic aromatic (HY-AR) and ring aromatic (RA)
features were used with other default values to generate
ten pharmacophore models using 3D QSAR pharmaco-
phore generation of DS. Each feature of the resulting
models occupies a certain weight that is proportional to
its relative contribution to biological activity. HypoGen
therefore constructs pharmacophore models correlating
best with biological activities and consisting of as few fea-
tures as possible. The HypoGen pharmacophore model
generation process is performed in three steps such as
the constructive phase, the subtractive phase and the
optimization phase [23,24]. Hypotheses that are common
to the most active set of compounds are identified during
the constructive phase. HypoGen calculates all possible
pharmacophore configurations using all combinations of
pharmacophore features for each of the conformations of
the two most active compounds. Additionally, the
hypotheses must fit a minimum subset of features of the
remaining most active compounds in order to be consid-
ered. A large database of pharmacophore configurations
is generated at the end of the constructive phase. In the
subtractive phase, all pharmacophore configurations that
are also present in the least active set of molecules are
removed. All compounds whose activity is by default 3.5
orders of magnitude less than that of the most active
compound are considered to represent the least active
molecules. The value 3.5 is adjustable depending on the
activity range of the training set. During the optimization
phase, the hypothesis score is improved. Hypotheses are
scored based on errors in activity estimates from regres-
sion and complexity. The optimization involves a variation
of features and/or locations to optimize activity prediction
via a simulated annealing approach. When the optimiza-
tion process no longer improves the score, HypoGen stops
and reports the top scoring 10 unique pharmacophores.
The generated pharmacophore models were evaluated for
their reliability based on the cost parameters. The overall
costs of a model consist of three cost components, namely,
the weight cost, the error cost, and the configuration cost.
The weight component is a value that increases in a Gaus-
sian form as this function weights in a model deviate from
the ideal value of two. The error cost represents the differ-
ence between estimated and measured activities of the
training set. The configuration cost quantifies the entropy
of the hypothesis space.
In addition, the following three cost values are calculated
during the generation of pharmacophore models: the fixed
cost, the total cost, and the null cost. The fixed cost is the
lowest possible cost representing a hypothetical simplest
model that fits all data perfectly. Fixed costs are calculated
by adding the minimum achievable error and weight cost
and the constant configuration cost. Another cost para-
meter, the null cost, represents the maximum cost of a
pharmacophore with no features and estimates activity to
be the average of activity data of training set molecules.
The null cost value is equal to the maximum occurring
error cost. For every pharmacophore generation ten total
cost values and each of fixed cost and null cost values are
calculated by the pharmacophore generation protocol in
the unit of bits. For a meaningful pharmacophore model,
the fixed cost should be lower and the null cost should be
higher and the total cost value should be closer to the
fixed cost and away from the null cost value [25,26].
HypoGen further estimates the activity of each training set
compound using regression parameters. The parameters
were computed by regression analysis using the relation-
ship of geometric fit value versus the negative logarithm of
activity. The better the geometric fit the greater the activ-
ity prediction of the compound. Along with these cost
values, other statistical values such as correlation coeffi-
cient and root mean square deviation (RMSD) were calcu-
lated. The best pharmacophore model was selected based
on the large cost difference, high correlation coefficient
and lower RMSD.
Pharmacophore validation
The main purpose to validate the generated pharmaco-
phore models is to investigate their ability to estimate the
activity of new compounds identified through database
screening or designed de novo. The selected pharmaco-
phore model was validated using three methods based on
the derived cost components, ability in test set prediction,
Fischer randomization test results, and leave-one-out
method. A larger difference between the fixed and null
costs than that between the fixed and total costs signifies
t h eq u a l i t yo fap h a r m a c o p h o r em o d e l .A l lo ft h e s ec o s t
values are reported in bits and a difference of 40-60 bits
between the total and null costs suggests a 75-90% chance
of representing a true correlation in the data [27,28].
Ninety three diverse compounds were used as the test set
to validate the pharmacophore model. Fischer randomiza-
tion is another approach for pharmacophore model valida-
tion. The 95% confidence level was selected in this
validation study and 19 random spreadsheets were con-
structed. This validation method checks the correlation
between the chemical structures and biological activity.
This method generates pharmacophore models using the
same parameters as those used to develop the original
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the training set compounds. Finally the cross validation of
the model was performed by using the leave-one-out
methodology. In this method, 18 pharmacophore models
were generated with the same parameters used for gener-
ating original pharmacophore model but leaving one com-
pound at a time from 18 training set compounds to
ensure the influence of every single training set compound
in the generation of selected pharmacophore model
[29,30].
Database screening and drug-like prediction
The best pharmacophore model validated using different
methods was used as a 3D query in database screening to
retrieve chemical compounds that fit all the pharmaco-
phoric features. A chemical compound must fit all the fea-
t u r e st ob ep i c k e da sh i t s .Search 3D Database protocol
with Best/Flexible search option was employed in database
screening. Three chemical databases of diverse chemical
compounds were screened for novel chemical scaffolds to
be used in potent renin inhibitor design. The identified
database hits were screened using various filters based on
estimated activity, Lipinski’s rule of five [31], and ADMET
properties [32-35].
Molecular docking
Compounds satisfying all the filters were subjected to
molecular docking studies. The GOLD (Genetic Optimiza-
tion for Ligand Docking) program from Cambridge Crys-
tallographic Data Centre, UK uses a genetic algorithm to
dock the small molecules into the protein active site was
used in molecular docking [36]. GOLD allows for a full
range of flexibility for the ligands and partial flexibility of
the protein. Protein coordinates from the crystal structure
complex of renin with aliskiren (PDB ID: 2V0Z), one of
the most active inhibitors, determined at a resolution of
2.20 Å were used to define the active site. The active site
was defined with a 10 Å radius around the bound inhibi-
tor. All the water molecules except two catalytically
important 184 and 250 were removed from the protein
and hydrogens were added. The ten top-scoring confor-
mations of every ligand were saved at the end of the calcu-
lation. Early termination option was used to skip the
genetic optimization calculation when any five conforma-
tions of a particular compound were predicted within an
R M S Dv a l u eo f1 . 5Å .T h eG O L Df i t n e s ss c o r ei sc a l c u -
lated from the contributions of hydrogen bond and van
der Waals interactions between the protein and ligand,
intramolecular hydrogen bonds and strains of the ligand
[37,38]. Protein-ligand interactions were analyzed using
DS and Molegro Virtual Docker [39] programs. The
novelty of the final hits was confirmed using SciFinder
[40] and PubChem [41] structure search tools.
Density functional theory (DFT) calculations
The final hits along with some most and least active
compounds were used as input and all DFT calculations
were carried out using Gaussian version 3.0 program.
The geometry optimization of a set of compounds was
carried out using the Becke3 Lee-Yang-Parr correlation
functional (B3LYP), at the 6-31G* level [42-45]. The orbi-
tal energies of frontier orbitals, namely, highest occupied
molecular orbital (HOMO) and lowest unoccupied mole-
cular orbital (LUMO) were calculated for a set of com-
pounds. The calculation was performed to evaluate the
electronic properties of final hits to be compared with
the compounds in the training set [46].
Results and discussion
Pharmacophore generation
A set of ten pharmacophore models was generated using
a training set containing 18 compounds by selecting
HBA, HBD, HY-AL, HY-AR and RA features as sug-
gested by Feature Mapping protocol. All the generated
pharmacophore models composed of either HBA or
HBD or both with HY-AL or HY-AR features. The total
cost values of ten pharmacophore models ranged from
81.50 to 99.54. The cost difference between the total
c o s ta n dn u l lc o s tm u s tb eg r e a t e ra n di ts h o u l db e
smaller between total cost and fixed cost values for a
significant pharmacophore model. In our study, the
pharmacophore generation run calculated a fixed cost
value of 70.08 and the null cost value of 148.56. Among
the total cost values of generated ten pharmacophore
models, first model (Hypo1) has scored the value closer
to the fixed cost value when compared to other models.
The cost difference between the null cost and total cost
value of the first pharmacophore model is 67.06 (Table
1). The cost difference value between 40 and 60 implies
that the pharmacophore model correlates the experi-
mental and estimated activity values more than 90%. In
this study, the cost difference value of Hypo1 signifies
that it can correlate the experimental and estimated
activity values of the training set compounds more than
90%. Hypo1 was made of four pharmacophoric features
consisting two HBA, one HBD and one HY-AL features
(Figure 2).
Further evaluation of the generated pharmacophore
models was based on the correlation coefficient. The
correlation values of these ten pharmacophore models
were greater than 0.840, and the first three pharmaco-
phore models correlated the activity data with high cor-
relation values, i.e., above 0.9. These results indicate the
capability of the pharmacophore model to predict the
activity of the training set compounds. Hypo1 showed
the highest correlation coefficient value of 0.944, high-
lighting its strong predictive ability. In addition, RMSD
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less than 1.5, further supporting the predictive ability of
the top pharmacophore models. Among the ten phar-
macophore models, Hypo1 was developed with better
statistical values, such as higher correlation, large cost
difference and lower RMSD (1.080). Hypo1 has pre-
dicted the experimental activity values of training set
compounds with high correlation. All of the compounds
in the training set and test set were categorized into
four different groups based on their experimental activ-
ity (IC50) values: most active (IC50 ≤ 10nM, ++++),
active (10< IC50 ≤ 200nM, +++), moderately active
(200< IC50 ≤ 1000 nM, ++), and inactive (IC50
>1000nM, +). The predictive ability of Hypo1 on train-
ing set compounds is shown in Table 2. Activity values
of 15 out of 18 compounds in the training set were pre-
dicted within their experimental activity scale where
compound 9, 13, and 14 were overestimated as active.
None of the calculated error values that represent the
ratio between the experimental and predicted activity
values were more than one order of magnitude. All of
the three most active compounds in the training set
were predicted very closely to their activity values indi-
cating the predictability of Hypo1. The most active com-
pounds in training set mapped all the features of Hypo1
whereas the other compounds miss any one of the phar-
macophoric features. The pharmacophore mapping of
most and least active compounds are shown in Figure 3.
The Hypo1 was selected as best model over Hypo2
which has also shown a high correlation value (0.928)
close to that of Hypo1 (0.944) because of the HBA fea-
tures. These HBA features generated in Hypo1 was
similar to the structure-based pharmacophore model
developed by our group recently [47]. These important
HBA features are not generated in Hypo2. In addition,
the energy values of the conformations of the most
active compounds in the training set used in model gen-
eration were lower in Hypo1 but relatively higher in
Hypo2. These analyses have also supported the reliabil-
ity of Hypo1 along with the high correlation coefficient.
Table 1 Statistical results of the top 10 pharmacophore hypotheses generated by HypoGen algorithm
Hypothesis Total cost Cost difference RMSD Correlation Features
Hypo1 81.50 67.06 1.080 0.944 HBA, HBA, HBD, HY-AL
Hypo2 88.05 60.51 1.247 0.928 HBD, HY-AL, HY-AL, HY-AR
Hypo3 90.28 58.28 1.388 0.908 HBA, HBA, HY-AL, HY-AR
Hypo4 92.63 55.93 1.565 0.878 HBA, HBD, HY-AR, HY-AR
Hypo5 95.59 52.97 1.596 0.875 HBA, HBA, HY-AL, HY-AR
Hypo6 97.63 50.93 1.737 0.847 HBD, HBD, HY-AL, HY-AL
Hypo7 97.71 50.85 1.720 0.851 HBA, HBD, HY-AL, HY-AR
Hypo8 98.80 49.76 1.662 0.866 HBA, HBD, HY-AL, HY-AR
Hypo9 98.85 49.71 1.631 0.873 HBD, HBD, HY-AL, HY-AR
Hypo10 99.54 49.02 1.779 0.840 HBA, HBA, HBD, HY-AL
Null cost = 148.56; fixed cost = 70.08; configuration cost = 16.7.
aCost difference = null cost – total cost.
bHBA, hydrogen-bond acceptor; HBD, hydrogen-bond donor; HY-AL, hydrophobic aliphatic; HY-AR, hydrophobic aromatic.
Figure 2 The best HypoGen pharmacophoremodel, Hypo1. (A) Chemical features present in Hypo 1 (B) 3D spatial arrangement and the
distance constraints between the chemical features. Green color represents HBA, magenta color represents HBD and cyan color represents HY-
AL features.
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The best pharmacophore model, Hypo1, was validated
using 93 test set compounds, which are diverse compar-
ing to the training set compounds. The Ligand Pharma-
cophore Mapping protocol with the Best Flexible Search
option was used to map every test set compound and the
estimated activity values were predicted for each com-
pound. The simple regression between the experimental
and estimated activity values of the test set compounds
showed a correlation coefficient value of 0.903 (Figure 4).
Table 2 Experimental and estimated IC50 values of the training set compounds based on best pharmacophore
hypothesis Hypo1




Experimental Estimated Experimental Estimated
1 0.5 0.40 -1.3 9.30 ++++ ++++
2 3 3.7 1.2 8.33 ++++ ++++
3 7 7.3 1.0 8.03 ++++ ++++
4 23 158 6.9 6.69 +++ +++
5 48 130 2.7 6.77 +++ +++
6 66 148 2.2 6.72 +++ +++
7 120 164 1.4 6.67 +++ +++
8 180 151 -1.2 6.71 +++ +++
9 206 144 -1.4 6.72 ++ +++
10 255 235 -1.1 6.52 ++ ++
11 300 414 1.4 6.27 ++ ++
12 364 417 1.1 6.28 ++ ++
13 430 126 -3.4 6.80 ++ +++
14 550 187 -2.9 6.62 ++ +++
15 820 501 -1.6 6.19 ++ ++
16 1020 1280 1.3 5.78 + +
17 1700 1088 -1.6 5.85 + +
18 5590 1838 -3.0 5.63 + +
aPositive value indicates that the estimated IC50 is higher than the experimental IC50; negative value indicates that the estimated IC50 is lower than the
experimental IC50.
bFit value indicates how well the features in the pharmacophore map the chemical features in the compound.
cActivity scale: IC50 ≤10nM (Most active, ++++); 10 < IC50 ≤ 200nM (Active, +++); 200 < IC50 ≤ 1000nM (Moderately active, ++); > 1000nM (Inactive, +).
Figure 3 Pharmacophore Mapping. (A) Mapping of the most active compound 1 in the training set on the best pharmacophore model
Hypo1. (B) Mapping of the least active compound 18 in the training set on the best pharmacophore model Hypo1. In the pharmacophore
model green represents HBA, magenta represents HBD and cyan represents HY-AL features.
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dicted in a different activity scale with a success rate of
94.62%. Two ‘most active’ compounds were underesti-
mated to ‘active’ s c a l ea n do n ec o m p o u n df r o mt h e
‘active’ scale was underestimated in ‘moderately active’
scale. Two ‘moderately active’ compounds were underes-
timated in ‘inactive’ scale. All compounds from the ‘inac-
tive’ scale were predicted within their activity scale (1
Table A1).
In addition, Hypo1 was further validated using Fischer
randomization test to testify that this pharmacophore
model is not resulted due to the random correlation. The
experimental activities of the training set were scrambled
randomly and the resulting training set was used in
HypoGen with the parameters chosen for the original
pharmacophore generation. A set of 19 random spread-
sheets was generated to achieve a 95% confidence level
that the best pharmacophore Hypo1 was not generated
by chance. None of the randomly generated pharmaco-
phore models during Fischer randomization test has
scored better statistical parameters than Hypo1. Though
there were five random pharmacophores scored a corre-
lation value above 0.9 none of their RMSD values were
lower than Hypo1 (Table 3).
The final validation was performed using leave-one-out
method, this method is used to verify whether the corre-
lation between the experimental and predicted activities
is mainly depend on one particular molecule in the train-
ing set. This is done by recomputing the pharmacophore
m o d e lb ye x c l u d i n go n em o l e c u l ea tat i m e .C o n s e -
quently, 18 HypoGen calculations were carried out under
the same conditions, used in the generation of original
Figure 4 Correlation plots. Correlation graph between the experimental activity and the estimated activity for the training set and test set
compounds.
Table 3 Results of Fischer’s randomization test
Validation no. Total cost Fixed cost RMSD Correlation
Original hypothesis
Hypo1 81.50 70.08 1.080 0.944
Randomized hypotheses
Trial1 95.892 70.080 1.661 0.862
Trial2 100.32 70.212 1.708 0.857
Trial3 92.248 65.837 1.531 0.890
Trial4 87.507 67.786 1.421 0.902
Trial5 93.581 68.931 1.653 0.863
Trial6 89.344 71.436 1.299 0.920
Trial7 87.886 66.944 1.464 0.895
Trial8 101.135 70.080 1.633 0.877
Trial9 98.448 68.674 1.764 0.844
Trial10 94.837 65.837 1.649 0.868
Trial11 99.687 71.629 1.663 0.865
Trial12 91.806 69.736 1.562 0.877
Trial13 107.608 70.080 2.021 0.787
Trial14 92.806 69.736 1.470 0.897
Trial15 101.133 69.688 1.866 0.822
Trial16 87.621 71.436 1.340 0.912
Trial17 90.393 70.212 1.357 0.913
Trial18 84.474 65.837 1.377 0.908
Trial19 98.957 70.268 1.722 0.852
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ing sets, each composed of 17 molecules. The result is
positive if none of the correlation coefficients of newly
generated pharmacophore models is higher or too lower
to that of Hypo1. From our results it was observed that
none of the 18 new models generated by this method has
shown any meaningful difference compared to Hypo1
(data not shown). This result supports and increases the
confident level of Hypo1 that its correlation coefficient
does not depend on one particular compound in the
training set. Based on these validation results, Hypo1 was
used as 3D query in database screening to identify the
diverse chemical compounds to be utilized in potent
renin inhibitor design.
Database screening
The best pharmacophore model, Hypo1, was used as a 3D
query to search three chemical databases, namely, NCI
(260,071 compounds), Maybridge (59,632) and Chem-
bridge (50,000) containing totally 369,703 compounds.
Search 3D Database protocol with the Best Search option
as available in DS was employed to search these databases.
The hit compounds were, primarily, filtered based on the
estimated activity value followed by drug-likeness predic-
tion. Lipinski’sr u l eo ff i v ea n dA D M E Tp r o p e r t i e sw e r e
used to select the compounds with favorable drug-like
properties. A compound has to obey the following para-
meters to be predicted as Lipinski-positive: (i) molecular
weight less than 500 (ii) number of hydrogen bond donors
and acceptors less than 5 and 10, respectively and (iii)
octanol / water partition coefficient value less than 5.
Fifty-three drug-like compounds along with the training
set compounds were subjected to molecular docking
study. Database screening and drug-likeness prediction
steps are shown in detail in Figure 5.
Molecular docking
The drug-like hit compounds along with the training set
compounds were docked into the active site. The active
site was defined based on the bound inhibitor, aliskiren,
in a crystal structure of renin (PDB code 2V0Z). The
binding modes, molecular interactions with the active
site components and GOLD fitness scores were consid-
ered as important components in selecting the best
Figure 5 Database screening. The flow of procedure used in 3D QSAR pharmacophore modeling.
John et al. BMC Bioinformatics 2011, 12(Suppl 14):S4
http://www.biomedcentral.com/1471-2105/12/S14/S4
Page 9 of 14poses of the docked compounds. The active site residues
were identified from the protein-ligand interactions
observed from the aliskiren-renin complex. Based on the
molecular interactions of aliskiren, the new database hits
were evaluated. Along with two catalytically important
aspartate residues, two active site water molecules were
also given importance as aliskiren interacts with them.
Compound 1 in the training set has scored a GOLD fit-
ness score of 41.22 and formed hydrogen bond interac-
tions with Asp32 and Gly217. It has also interacted
hydrophobically with other active site amino acids
(Figure 6A). Twenty-five hit compounds scoring a GOLD
fitness score value greater than that of Compound 1 were
selected and their binding modes and molecular interac-
tions were analyzed. Finally, two compounds namely
HTS05096 and AW00695 from Maybridge database were
chosen based on hydrogen bond interactions with two
aspartic acid residues and one of two water molecules as
well as the other active site residues. HTS05096 has
scored the Hypo1estimated activity value of 0.78 along
with the GOLD fitness score of 49.38. This compound
has formed hydrogen interactions with both the aspartic
acid residues and a water molecule in the active site (Fig-
ure 6B). It has also formed hydrophobic interactions with
Phe117 and other active site residues. The second hit,
AW00695, interacted with aspartic acid residues (Asp32
and Asp215), S76 and one of the active site water mole-
cule, HOH184, as well as the hydrophobic interactions
with active residues (Figure 6C). The pharmacophore
overlay of this hit revealed that the parts overlaid on
HBD and HBA features are involved in polar contacts
with aspartate and serine residues in the active site
whereas the HY-AL part is positioned towards the
Phe117 enabling hydrophobic interactions. Figure 6D
shows the overlay of compound 1 and two hit com-
pounds in the active site. The pharmacophore mapping
and 2D representation of these compounds are shown in
Figs. 7 and 8, respectively.
The interaction between the protein and the ligand
molecules were observed using DS and Molegro Virtual
Figure 6 Molecular docking experiments of 3D QSAR pharmacophore modeling. Compound 1, the most active compound in the training
set is shown in blue color whereas HTS05096 and AW00695 are shown in green and red colors, respectively. Molecular overlay of all the three
compounds is shown at lower right figure. Hydrogen bond interactions are shown in black dotted lines.
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Page 10 of 14Docker. The novelty of the two final hit compounds was
confirmed using SciFinder search and PubChem search.
Density Functional Theory calculations
The DFT calculations for a set including two final hits,
two most active, and a least active compounds were per-
formed in order to study the electronic properties such
as HOMO and LUMO. The values of energy gaps (ΔE)
were calculated for all the compounds. The energy gaps
have been calculated as the difference of the energies
between the LUMO and the HOMO. The energy gap
values of the 5 compounds ranged from 0.16174 to
0.19811 eV. The energy gap between the LUMO and
HOMO elucidates the reactivity of the molecule that is
the smaller the gap and the more reactive is the molecule
[48,49]. Figure 9 shows the plot of energy gap values cal-
culated for two final hits, two most active and a least
active compounds. The Hit1, HTS05096, showed the
minimum energy gap value of 0.163 and the least active
compound 18 showed the maximum energy gap value of
0.198. Hit 2, AW00695, has shown a value of 0.179
whereas the two most active compounds, namely com-
pound 1 and 2, have shown the energy gap values of
0.178 and 0.186, respectively. This observation revealed
that the final hit compounds have shown smaller energy
gap values than the most active compounds thereby indi-
cated their high reactivity. The calculated energy gap
values have shown good correlation with the biological
activity values. From this analysis it was observed that the
final hit compounds have displayed the better or similar
electronic properties compared to the most active com-
pounds in the training set. These results have also pro-
vided the confidence on the quality of the developed
pharmacophore model, Hypo1.
Conclusions
In the present work, a quantitative pharmacophore
model, Hypo1, was developed based on the training set
Figure 7 Pharmacophore mapping of final database hit compounds on the best pharmacophore model Hypo1. (A) HTS05096
represented in blue color (B) AW00695 represented in orange color. In the pharmacophore model green represents HBA, magenta represents
HBD and cyan represents HY-AL features.
Figure 8 Chemical structures of hit compounds. 2D representation of final hits HTS05096 and AW00695.
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Page 11 of 14compounds with a high diversity in terms of chemical
structures and biological activity values. The best phar-
macophore model was selected based on various para-
meters such as cost difference, correlation co-efficient
and validation results. Hypo1 was generated with one
HY-AL, one HBD and two HBA features with a high
correlation coefficient value of 0.944. The validation
methods included test set prediction, Fischer randomiza-
tion, and leave-one-out method. The external test set
containing 93 compounds was used in validating the
ability of Hypo1 in predicting the activities of com-
pounds that are not included in training set. Hypo1 has
predicted this test set with a high correlation value of
0.903. The second validation based on Fischer randomi-
zation has proved that Hypo1 was not generated by a
chance correlation in the training set. The leave-one-out
validation proved that the correlation coefficient of
Hypo1 did not depend on one particular compound in
the training set. All these validation procedures have
shown the strength of the selected model, Hypo1, in
predicting the active compounds. After observing the
validation results, Hypo1 was used in database screening
to identify hits that can be used in potent renin inhibitor
design. The identified hit compounds were further fil-
tered based on the binding mode and molecular interac-
tions at the active site of renin. The final hits reported as
potential lead compounds have scored high estimated
activity, favorable drug-like properties and strong mole-
cular interactions with the catalytic residues at the active
site. The DFT calculations were performed to study the
electronic properties of the hit compounds and thereby
to validate the quality of the pharmacophore model,
Hypo1. The final hits, HTS05096 and AW00695, showed
the minimum energy gaps which represent the more
reactivity of the hit compounds when compare to the
most active compounds. This provided the confidence on
the inhibitory property of the final hit compounds. Thus,
these hits can be utilized in designing future class of
novel renin inhibitors.
Additional material
Additional file 1: Table A1 Comparison of experimental and
estimated IC50 values of the test set compounds based on best
pharmacophore hypothesis Hypo1.
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